The Annals New | Pharmaco Epidemiology and Therapeutic Risk Management
home help contact us subscription past issues search current issue
 QUICK SEARCH:   [advanced]


     


Drug Intelligence & Clinical Pharmacy: Vol. 22, No. 12, pp. 979-980.
© 1988 Harvey Whitney Books Company.
This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Articles Ahead of Print
Right arrow [Order Reprint]
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bramhall, D
Right arrow Articles by Levine, M
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bramhall, D
Right arrow Articles by Levine, M


Research Articles

Possible interaction of ranitidine with phenytoin

D Bramhall and M Levine

Clinical and animal studies have shown that cimetidine and ranitidine can inhibit hepatic cytochrome P-450-mediated metabolism of a variety of other drugs. This occurs to a lesser extent with ranitidine than with cimetidine at doses commonly used to treat gastric acid-related disorders. We recently observed a 66-year-old man whose steady-state serum phenytoin concentration increased 40 percent during one month after the addition to his regimen of ranitidine 150 mg bid. Because the ranitidine had been prescribed postsurgically for prophylaxis, it was discontinued and the patient's serum phenytoin concentration declined to the previous steady-state level with no change in dose or other drug therapy. This case indicates that the serum phenytoin concentration should be monitored for the first month after the addition of ranitidine to the regimens of patients on chronic phenytoin therapy. As well, further clinical investigation of factors affecting the interindividual inhibitory action of ranitidine is warranted.


This article has been cited by other articles:


Home page
J Clin PharmacolHome page
W. A. Maish, M. M. McCubbin, L. G. Letzig, H. C. Farrar III, and G. L. Kearns
Pharmacokinetics of Famotidine in Patients with Cystic Fibrosis
J. Clin. Pharmacol., November 1, 1998; 38(11): 1010 - 1016.
[Abstract] [PDF]




homecopy help contact us subscription past issues search current issue
Copyright © 1988 by Harvey Whitney Books Company.